NEW YORK, May 7 -- CombiMatrix announced today that it has produced pools of siRNA that target the SARS coronavirus.
The Washington-based subsidiary of Acacia Research said it is collaborating with the National Institutes of Health and the US Army Medical Research Institute of Infectious Diseases to screen the siRNA samples against the virus.
The company had previously developed a microarray, using the genome sequences prepared by scientists in the US, Canada and Asia. The company produced an array with controls, and PCR probes and linkers for transcription.
The company is targeting two genes of the virus believed to be replication regulators -- an RNA-dependent polymerase, and the other an NTPase/helicase domain.
The company has applied for patents on the molecules and said that it plans to offer drug candidates to partners to complete pre-clinical and clinical development if the molecules show efficacy in initial tests.
GenomeWeb/Newsletters' coverage of SARS
Canadian Team Sequencing SARS Virus (Apr 9, 2003)
CDC Hails SARS Virus Sequencing, Discusses PCR Diagnostic Development (Apr 14, 2003)
CDC Completes SARS Virus Genome Draft On Heels of Canadian Team (April 14, 2003)
Canadian Team Leader: SARS Coronavirus Genome Has 11 Novel ORFs (April 15, 2003)
CombiMatrix Creates Microarray Based on SARS Genome Data (April 16, 2003)
Coronavirus Linked to SARS: WHO (April 16, 2003)
Singapore Genome Institute Joins SARS Sequencing Fray (April 16, 2003)
CombiMatrix's Ali Arjomand on Developing a SARS Microarray (BioArray News, April 25, 2003)
Roche to Launch RT-PCR-based SARS Diagnostic by July (April 28, 2003)
Canadian, US, Chinese Teams Publish SARS Genome Sequence (May 2, 2003)
Focus Tech Claims First RT-PCR SARS Diagnostic (May 5, 2003)
Affymetrix to Offer SARS GeneChip (May 6, 2003)